CL2022000558A1 - Conjugado persistente de triple activador que activa el receptor de glucagón, glp-1 u gip (divisional 2 solicitud 202002033) - Google Patents

Conjugado persistente de triple activador que activa el receptor de glucagón, glp-1 u gip (divisional 2 solicitud 202002033)

Info

Publication number
CL2022000558A1
CL2022000558A1 CL2022000558A CL2022000558A CL2022000558A1 CL 2022000558 A1 CL2022000558 A1 CL 2022000558A1 CL 2022000558 A CL2022000558 A CL 2022000558A CL 2022000558 A CL2022000558 A CL 2022000558A CL 2022000558 A1 CL2022000558 A1 CL 2022000558A1
Authority
CL
Chile
Prior art keywords
gip
glp
divisional
activates
application
Prior art date
Application number
CL2022000558A
Other languages
English (en)
Inventor
Euh Lim Oh
Jong Suk Lee
Young Jin Park
Chang Ki Lim
Sung Youb Jung
Se Chang Kwon
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of CL2022000558A1 publication Critical patent/CL2022000558A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a un conjugado de acción prolongada de un agonista triple que tiene actividades en cada uno del receptor de glucagón, GLP-1, y GIP, y uso del mismo.
CL2022000558A 2015-12-31 2022-03-07 Conjugado persistente de triple activador que activa el receptor de glucagón, glp-1 u gip (divisional 2 solicitud 202002033) CL2022000558A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20150191082 2015-12-31
KR20160163737 2016-12-02

Publications (1)

Publication Number Publication Date
CL2022000558A1 true CL2022000558A1 (es) 2022-09-23

Family

ID=59225193

Family Applications (6)

Application Number Title Priority Date Filing Date
CL2018001776A CL2018001776A1 (es) 2015-12-31 2018-06-28 Agonista triple de receptores de glucagón/glp-1/gip
CL2018001795A CL2018001795A1 (es) 2015-12-31 2018-06-29 Conjugado persistente de triple activador que activa el receptor de glucagón, glp-1 u gip
CL2020002033A CL2020002033A1 (es) 2015-12-31 2020-08-05 Conjugado persistente de triple activador que activa el receptor de glucagón, glp-1 u gip. (divisional solicitud 201801795)
CL2020002034A CL2020002034A1 (es) 2015-12-31 2020-08-05 Agonista triple de receptores de glucagón/glp-1/gip. (divisional solicitud 201801776)
CL2022000557A CL2022000557A1 (es) 2015-12-31 2022-03-07 Agonista triple de receptores de glucagón/glp-1/gip (divisional 2 solicitud 202002034)
CL2022000558A CL2022000558A1 (es) 2015-12-31 2022-03-07 Conjugado persistente de triple activador que activa el receptor de glucagón, glp-1 u gip (divisional 2 solicitud 202002033)

Family Applications Before (5)

Application Number Title Priority Date Filing Date
CL2018001776A CL2018001776A1 (es) 2015-12-31 2018-06-28 Agonista triple de receptores de glucagón/glp-1/gip
CL2018001795A CL2018001795A1 (es) 2015-12-31 2018-06-29 Conjugado persistente de triple activador que activa el receptor de glucagón, glp-1 u gip
CL2020002033A CL2020002033A1 (es) 2015-12-31 2020-08-05 Conjugado persistente de triple activador que activa el receptor de glucagón, glp-1 u gip. (divisional solicitud 201801795)
CL2020002034A CL2020002034A1 (es) 2015-12-31 2020-08-05 Agonista triple de receptores de glucagón/glp-1/gip. (divisional solicitud 201801776)
CL2022000557A CL2022000557A1 (es) 2015-12-31 2022-03-07 Agonista triple de receptores de glucagón/glp-1/gip (divisional 2 solicitud 202002034)

Country Status (32)

Country Link
US (6) US10370426B2 (es)
EP (3) EP3398961B1 (es)
JP (5) JP6712322B2 (es)
KR (8) KR20170080522A (es)
CN (6) CN115920077A (es)
AU (4) AU2016382394B2 (es)
BR (2) BR112018013530A2 (es)
CA (2) CA3010265A1 (es)
CL (6) CL2018001776A1 (es)
CO (2) CO2018006982A2 (es)
CR (2) CR20180380A (es)
DK (1) DK3398961T3 (es)
DO (2) DOP2018000157A (es)
EA (2) EA038544B1 (es)
EC (2) ECSP18053053A (es)
ES (1) ES2925098T3 (es)
HK (2) HK1255834A1 (es)
HR (1) HRP20220995T1 (es)
HU (1) HUE059737T2 (es)
IL (2) IL260310B2 (es)
MX (2) MX2018008128A (es)
PE (1) PE20181494A1 (es)
PH (2) PH12018501409A1 (es)
PL (1) PL3398961T3 (es)
PT (1) PT3398961T (es)
RS (1) RS63541B1 (es)
SA (2) SA518391891B1 (es)
SG (2) SG11201805573RA (es)
TN (2) TN2018000231A1 (es)
TW (4) TWI731015B (es)
WO (2) WO2017116205A1 (es)
ZA (2) ZA201804998B (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
AU2015242657B2 (en) * 2014-03-31 2020-05-21 Hanmi Pharm. Co., Ltd. Method for improving solubility of protein and peptide by using immunoglobulin Fc fragment linkage
WO2016108586A1 (ko) 2014-12-30 2016-07-07 한미약품 주식회사 안정성이 증가된 글루카곤 유도체
PE20240215A1 (es) 2015-06-30 2024-02-16 Hanmi Pharmaceutical Co Ltd Derivado de glucagon y una composicion que comprende un conjugado de accion prolongada del mismo
TN2018000231A1 (en) 2015-12-31 2019-10-04 Hanmi Pharm Ind Co Ltd Long-acting conjugate of triple glucagon/glp-1/gip receptor agonist
EP3479841A4 (en) 2016-06-29 2020-03-04 Hanmi Pharm. Co., Ltd. GLUCAGON DERIVATIVE, CONJUGATE THEREOF, COMPOSITION COMPRISING SAME, AND THERAPEUTIC USE THEREOF
JP2020506932A (ja) 2017-02-03 2020-03-05 ハンミ ファーマシューティカル カンパニー リミテッド 持続性が増加した生理活性物質の結合体及びその用途
JP7121024B2 (ja) 2017-02-07 2022-08-17 ハンミ ファーマシューティカルズ カンパニー リミテッド 非ペプチド性重合体リンカー化合物、そのリンカー化合物を含む結合体、及びそれらの製造方法
MX2019008449A (es) 2017-02-08 2019-09-09 Bristol Myers Squibb Co Polipetidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos.
JOP20180028A1 (ar) 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co مركب ببتيد
AR113486A1 (es) * 2017-12-21 2020-05-06 Lilly Co Eli Análogos de incretina y sus usos
TWI767095B (zh) 2017-12-21 2022-06-11 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
CN109239346B (zh) * 2018-10-31 2019-10-11 中国药科大学 一组代谢标志物在代谢综合征早期诊断方面的应用
US20220088148A1 (en) * 2018-12-21 2022-03-24 Hanmi Pharm, Co., Ltd. A pharmaceutical composition comprising insulin and trigonal glucagon/glp-1/gip receptor agonist
EP3939990A4 (en) * 2019-02-15 2023-05-24 Hanmi Fine Chemical Co., Ltd. NEW INTERMEDIATE USED FOR A BIOLOGICALLY ACTIVE POLYPEPTIDE AND METHOD FOR PREPARING IT
WO2020214013A1 (ko) * 2019-04-19 2020-10-22 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체의 고지혈증에 대한 치료적 용도
WO2020214012A1 (ko) * 2019-04-19 2020-10-22 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체를 포함하는 고지혈증 예방 또는 치료용 약학적 조성물 및 예방 또는 치료 방법
CN111944055B (zh) * 2019-05-16 2022-08-02 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
JP7111917B2 (ja) * 2019-06-28 2022-08-02 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン、ｇｌｐ－１及びｇｉｐ受容体の全てに対して活性を有する三重活性体又はその結合体の肝疾患に対する治療的使用
MX2022002115A (es) 2019-08-19 2022-03-17 Lilly Co Eli Metodos para preparar analogos de incretina.
US20230000950A1 (en) * 2019-10-04 2023-01-05 Hanmi Pharm. Co., Ltd. Composition comprising glucagon and glp-1 and gip receptor dual agonist and therapeutic use of same
CN114641303A (zh) 2019-11-11 2022-06-17 勃林格殷格翰国际有限公司 Npy2受体激动剂
AR120714A1 (es) 2019-12-18 2022-03-09 Lilly Co Eli Análogos de incretina y sus usos
CN111040022B (zh) * 2019-12-23 2021-12-14 万新医药科技(苏州)有限公司 针对胰高血糖素样肽-1受体、胰高血糖素受体、以及抑胃肽受体的三重激动剂
EP4085077A4 (en) 2019-12-31 2024-01-17 Beijing Ql Biopharmaceutical Co Ltd FUSION PROTEINS FROM GLP-1 AND GDF15 AND CONJUGATES THEREOF
EP4104849A4 (en) * 2020-01-13 2024-03-27 Hanmi Pharmaceutical Co Ltd THERAPEUTIC USE OF A LONG-ACTING CONJUGATE OF A TRIPLE AGONIST WITH ACTIVITY RELATED TO GLUCAGON AND GLP-1 AND GIP RECEPTORS AGAINST LUNG DISEASE
CN115916238A (zh) * 2020-04-20 2023-04-04 韩美药品株式会社 包含胰高血糖素/GLP-l/GIP受体三重激动剂或其缀合物的高血脂症预防或治疗组合物及其使用方法
JP2023526552A (ja) * 2020-05-22 2023-06-21 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン、ｇｌｐ－１及びｇｉｐ三重活性体の持続型結合体の液状製剤
JP2023535382A (ja) 2020-07-17 2023-08-17 ハンミ ファーマシューティカル カンパニー リミテッド 三重作用性持続型結合体又は三重作用剤を含む組合せ物の治療学的用途
BR112022025623A2 (pt) 2020-08-07 2023-03-07 Boehringer Ingelheim Int Agonistas solúveis de receptores de npy2
US20230302148A1 (en) 2020-08-14 2023-09-28 Hanmi Pharm. Co., Ltd. Pharmaceutical composition comprising long-acting conjugate of triple glucagon/glp-1/gip receptor agonist
MX2023001601A (es) 2020-08-14 2023-03-07 Hanmi Pharmaceutical Co Ltd Composicion farmaceutica hipotensora que comprende un activador triple que tiene actividad para todos los receptores de glucagon, glp-1, y gip.
CN116437967A (zh) 2020-09-25 2023-07-14 韩美药品株式会社 包括对胰高血糖素、glp-1和glp受体全部具有活性的三重激动剂或其缀合物的用于预防或治疗骨病的药物组合物
WO2022065899A1 (ko) 2020-09-25 2022-03-31 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체의 다발성 경화증의 치료 용도
WO2022065897A1 (ko) 2020-09-25 2022-03-31 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체의 신경퇴행성 질환의 치료 용도
CN115925994B (zh) 2020-09-30 2023-09-22 北京质肽生物医药科技有限公司 多肽缀合物和使用方法
WO2022080984A1 (ko) * 2020-10-16 2022-04-21 한미약품 주식회사 Gip 유도체, 이의 지속형 결합체, 및 이를 포함하는 약학적 조성물
US20230381333A1 (en) * 2020-10-16 2023-11-30 Hanmi Pharm. Co., Ltd. Pharmaceutical composition comprising glucagon/glp-1/gip triple agonist or long-acting conjugate thereof for preventing or treating vasculitis
JP2023546384A (ja) 2020-10-16 2023-11-02 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン、ｇｌｐ－１及びｇｉｐ受容体の全てに対して活性を有する三重活性体の呼吸器感染疾患の後遺症の治療用途
KR20220050822A (ko) * 2020-10-16 2022-04-25 한미약품 주식회사 글루카곤/glp-1/gip 삼중작용제 또는 이의 지속형 결합체를 포함하는 루푸스-관련 질환의 예방 또는 치료용 약학적 조성물
CN116635055A (zh) * 2020-10-16 2023-08-22 韩美药品株式会社 包括gip衍生物或其长效缀合物的用于预防或治疗狼疮相关疾病的药物组合物
JP2023550594A (ja) 2020-10-30 2023-12-04 ノヴォ ノルディスク アー／エス Ｇｌｐ－１、ｇｉｐ、およびグルカゴン受容体三重作動薬
MX2023006419A (es) * 2020-12-02 2023-08-15 Dongbao Purple Star Hangzhou Biopharmaceutical Co Ltd Compuestos polipéptidos modificados con lactama.
EP4269425A1 (en) 2020-12-24 2023-11-01 Hanmi Pharm. Co., Ltd. Novel triple activator that activates all of glucagon, glp-1 and gip receptors, and use thereof
WO2022164222A2 (ko) * 2021-01-29 2022-08-04 한미약품 주식회사 Gip 유도체 또는 이의 지속형 결합체를 포함하는 폐질환의 예방 또는 치료용 약학적 조성물
KR20240013798A (ko) 2021-05-26 2024-01-30 더 유나이티드 바이오-테크놀로지 (헝친) 컴퍼니 리미티드 다중 작용제 및 이의 사용
KR20230004135A (ko) 2021-06-30 2023-01-06 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 조합물의 치료학적 용도
WO2023005841A1 (zh) * 2021-07-30 2023-02-02 南京明德新药研发有限公司 含内酰胺桥的多肽化合物
KR20230095665A (ko) * 2021-12-22 2023-06-29 한미약품 주식회사 간 표적 약물 및 이의 용도
WO2023169456A1 (en) 2022-03-09 2023-09-14 Gasherbrum Bio , Inc. Heterocyclic glp-1 agonists
WO2023179542A1 (en) 2022-03-21 2023-09-28 Gasherbrum Bio , Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
WO2023198140A1 (en) 2022-04-14 2023-10-19 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
TW202404997A (zh) * 2022-05-27 2024-02-01 韓商Ｄ＆Ｄ製藥科技股份有限公司 肽組合物及其使用方法

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5476304A (en) 1977-11-29 1979-06-18 Tokyo Printing Ink Mfg Co Ltd Ink
US5408037A (en) 1991-01-17 1995-04-18 Zymogenetics, Inc. Methods for detecting glucagon antagonists
GB9423277D0 (en) 1994-11-18 1995-01-11 Univ Nottingham Pulsed laser deposition of coatings
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
DE69731289D1 (de) 1996-03-18 2004-11-25 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
HU229108B1 (en) * 2000-06-16 2013-09-30 Lilly Co Eli Glucagon-like peptide-1 analogs
EP2275117B1 (en) * 2001-07-31 2016-10-26 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services GLP-1, exendin-4, peptide analogs and uses thereof
MXPA05009940A (es) * 2003-03-19 2005-12-05 Lilly Co Eli Compuestos de glp-1 de enlace de glicol polietilenico.
TW200522976A (en) * 2003-09-19 2005-07-16 Novo Nordisk As Novel plasma protein affinity tags
US8263084B2 (en) 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
ES2372495T3 (es) 2003-11-13 2012-01-20 Hanmi Holdings Co., Ltd Método para la producción en masa de la región constante de inmunoglobulina.
ES2495741T3 (es) * 2006-04-20 2014-09-17 Amgen, Inc Compuestos de GLP-1
US20080027072A1 (en) * 2006-04-20 2008-01-31 Ampla Pharmaceuticals, Inc. Potentiation of MC4 receptor activity
CN101578102B (zh) 2007-01-05 2013-07-17 印第安纳大学研究及科技有限公司 在生理性pH缓冲液中显示增强的溶解性的胰高血糖素类似物
US20090098130A1 (en) 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
JP2008169195A (ja) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
EP2111414B1 (en) 2007-02-15 2014-07-02 Indiana University Research and Technology Corporation Glucagon/glp-1 receptor co-agonists
DK2158214T3 (da) 2007-06-15 2011-12-05 Zealand Pharma As Glukagonanaloger
CN102015761A (zh) 2007-06-19 2011-04-13 大塚化学株式会社 附加糖链的glp-1肽
ES2672770T3 (es) 2007-09-05 2018-06-18 Novo Nordisk A/S Derivados del péptido-1 similar al glucagón y su uso farmacéutico
WO2009099763A1 (en) 2008-01-30 2009-08-13 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
PA8830501A1 (es) * 2008-06-17 2010-07-27 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1
EA020326B9 (ru) 2008-06-17 2015-03-31 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Агонисты смешанного действия на основе глюкозозависимого инсулинотропного пептида для лечения нарушений обмена веществ и ожирения
MX2010012695A (es) 2008-06-17 2011-03-15 Univ Indiana Res & Tech Corp Analogos de glucagon que exhiben solubilidad y estabilidad aumentadas en soluciones reguladoras de ph fisiologico.
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
WO2010148089A1 (en) 2009-06-16 2010-12-23 Indiana University Research And Technology Corporation Gip receptor-active glucagon compounds
JP6054742B2 (ja) 2009-07-13 2016-12-27 ジーランド ファーマ アクティーゼルスカブ アシル化グルカゴン類似体
GB0917072D0 (en) 2009-09-29 2009-11-11 Univ Ulster Peptide analogues of glucagon for diabetes therapy
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
EA026384B1 (ru) 2010-01-20 2017-04-28 Зилэнд Фарма А/С Лечение заболеваний сердца
KR20120123443A (ko) * 2010-01-27 2012-11-08 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트
JP5812627B2 (ja) * 2010-03-10 2015-11-17 公益財団法人相模中央化学研究所 改良Ｆｃ受容体およびその製造方法
JP6054861B2 (ja) 2010-03-26 2016-12-27 ノヴォ ノルディスク アー／エス 新規のグルカゴン類似体
EP2568993A4 (en) 2010-05-13 2014-02-19 Univ Indiana Res & Tech Corp GLUCAGON SUPERFAMILY PEPTIDES EXPRESSING G PROTEIN-COUPLED RECEPTOR ACTIVITY
KR101382593B1 (ko) 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
MA34885B1 (fr) 2010-12-22 2014-02-01 Indiana Unversity Res And Technology Corp Analogues du glucagon presentant una ctivite de recepteur de gip
WO2012150503A2 (en) 2011-05-03 2012-11-08 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
JP6284471B2 (ja) 2011-05-18 2018-02-28 メデリス ダイアビーティーズ，エルエルシー インスリン抵抗性のための改善されたペプチドの調合薬
UA113626C2 (xx) * 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
DK2718318T3 (en) 2011-06-10 2018-11-05 Hanmi Science Co Ltd New oxyntomodulin derivatives and pharmaceutical compositions for the treatment of obesity comprising these
WO2012173422A1 (en) 2011-06-17 2012-12-20 Hanmi Science Co., Ltd. A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
RU2014101697A (ru) * 2011-06-22 2015-07-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Коагонисты рецепторов глюкагона/glp-1
JP6396211B2 (ja) 2011-07-04 2018-09-26 インペリアル・イノベイションズ・リミテッド 新規化合物及び摂食行動に対するそれらの効果
BR112014007124A2 (pt) 2011-11-17 2017-06-13 Univ Indiana Res & Tech Corp superfamília de peptídeos gluxagon que exibem atividade no receptor glicocorticóide
CN107739409A (zh) 2012-05-18 2018-02-27 爱德迪安（北京）生物技术有限公司 用于糖尿病治疗的蛋白、蛋白缀合物及其应用
BR112014031671A2 (pt) * 2012-06-21 2018-08-07 Hoffmann La Roche análogos de glucagon exibindo atividade de receptor gip
TW201402611A (zh) * 2012-06-21 2014-01-16 Univ Indiana Res & Tech Corp 具有改變之ｆｃ效應子功能之腸促胰島素受體配體多肽ｆｃ區融合多肽及結合物
AR091477A1 (es) * 2012-06-21 2015-02-04 Univ Indiana Res & Tech Corp Analogos de glucagon que presentan actividad de receptor de gip
AR094821A1 (es) 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
KR101968344B1 (ko) * 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
AR092873A1 (es) * 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
EA034499B1 (ru) 2012-11-06 2020-02-13 Ханми Фарм. Ко., Лтд. Жидкая композиция белкового конъюгата, содержащего оксинтомодулин и фрагмент иммуноглобулина
CN104918961A (zh) 2012-11-20 2015-09-16 梅德瑞斯糖尿病有限责任公司 用于胰岛素抗性的改良的肽药物
DK2922877T3 (da) 2012-11-20 2019-01-02 Eumederis Pharmaceuticals Inc Forbedrede peptidlægemidler
KR20150096433A (ko) * 2012-12-21 2015-08-24 사노피 이중 glp1/gip 또는 삼중 glp1/gip/글루카곤 효능제
EP2986314A4 (en) * 2013-03-15 2016-04-13 Univ Indiana Res & Tech Corp PROTOCOLS AND A PROLONGED ACTION
BR112015025464A2 (pt) 2013-04-18 2017-10-10 Novo Nordisk As coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico
EP3033355A1 (en) 2013-08-16 2016-06-22 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
US10039809B2 (en) 2013-12-18 2018-08-07 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
AR100695A1 (es) 2014-05-30 2016-10-26 Hanmi Pharm Ind Co Ltd Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón
TWI802396B (zh) 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
CN108271356A (zh) * 2014-09-24 2018-07-10 印第安纳大学研究及科技有限公司 肠降血糖素-胰岛素缀合物
WO2016108586A1 (ko) 2014-12-30 2016-07-07 한미약품 주식회사 안정성이 증가된 글루카곤 유도체
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
PE20240215A1 (es) 2015-06-30 2024-02-16 Hanmi Pharmaceutical Co Ltd Derivado de glucagon y una composicion que comprende un conjugado de accion prolongada del mismo
TW201718629A (zh) 2015-09-25 2017-06-01 韓美藥品股份有限公司 包含多個生理多肽及免疫球蛋白Ｆｃ區之蛋白質接合物
EP3384935A4 (en) 2015-12-02 2019-08-21 Hanmi Pharm. Co., Ltd. PROTEIN COMPLEX UTILIZING A FATTY ACID DERIVATIVE, AND PROCESS FOR PREPARING THE SAME
TN2018000231A1 (en) * 2015-12-31 2019-10-04 Hanmi Pharm Ind Co Ltd Long-acting conjugate of triple glucagon/glp-1/gip receptor agonist

Also Published As

Publication number Publication date
ECSP18053055A (es) 2018-07-31
CN109071624A (zh) 2018-12-21
EP3398961B1 (en) 2022-06-29
SA518391903B1 (ar) 2022-08-01
US10981967B2 (en) 2021-04-20
KR102401869B1 (ko) 2022-05-25
JP2020171287A (ja) 2020-10-22
CL2020002034A1 (es) 2020-10-09
CL2018001776A1 (es) 2018-08-10
ZA201804997B (en) 2019-05-29
EP3398962A4 (en) 2019-08-07
BR112018013525A2 (pt) 2018-12-04
KR20170080521A (ko) 2017-07-10
TN2018000228A1 (en) 2019-10-04
CO2018006982A2 (es) 2018-07-10
EA038544B1 (ru) 2021-09-13
TW201737945A (zh) 2017-11-01
US20190002520A1 (en) 2019-01-03
IL260310B1 (en) 2023-10-01
AU2019203888B2 (en) 2021-05-13
US20190218269A1 (en) 2019-07-18
KR20200095436A (ko) 2020-08-10
CN108699125A (zh) 2018-10-23
CL2020002033A1 (es) 2020-10-09
DOP2018000157A (es) 2018-10-15
CN115920077A (zh) 2023-04-07
AU2019203888A1 (en) 2019-06-20
HRP20220995T1 (hr) 2022-11-11
KR102179391B1 (ko) 2020-11-16
CN116063453A (zh) 2023-05-05
EA201891360A1 (ru) 2018-12-28
PH12018501409A1 (en) 2019-04-08
KR102179392B1 (ko) 2020-11-16
EA201891359A1 (ru) 2019-01-31
AU2016382394B2 (en) 2019-07-04
PL3398961T3 (pl) 2022-09-26
IL260318B1 (en) 2023-10-01
TWI731015B (zh) 2021-06-21
TW202330585A (zh) 2023-08-01
KR20190060749A (ko) 2019-06-03
KR20170080522A (ko) 2017-07-10
PH12018501411A1 (en) 2019-04-08
EP3398961A1 (en) 2018-11-07
SG11201805573RA (en) 2018-07-30
BR112018013530A2 (pt) 2018-12-04
CN116063454A (zh) 2023-05-05
CR20180380A (es) 2018-12-07
AU2019203891B2 (en) 2021-05-13
HUE059737T2 (hu) 2022-12-28
ECSP18053053A (es) 2018-07-31
KR20190104958A (ko) 2019-09-11
KR102285377B1 (ko) 2021-08-04
PE20181494A1 (es) 2018-09-18
DK3398961T3 (da) 2022-08-22
MX2018008027A (es) 2018-11-29
PT3398961T (pt) 2022-09-05
JP2020128428A (ja) 2020-08-27
WO2017116205A1 (ko) 2017-07-06
MX2018008128A (es) 2018-12-06
TW202216748A (zh) 2022-05-01
US10400020B2 (en) 2019-09-03
EP3398961A4 (en) 2019-06-12
JP6712323B2 (ja) 2020-06-17
SG11201805586SA (en) 2018-07-30
EP3985017A1 (en) 2022-04-20
KR102367997B1 (ko) 2022-03-02
CA3010265A1 (en) 2017-07-06
AU2016382394A1 (en) 2018-08-02
DOP2018000159A (es) 2018-09-30
EA038524B1 (ru) 2021-09-09
CL2018001795A1 (es) 2018-08-10
CO2018006986A2 (es) 2018-07-10
IL260310B2 (en) 2024-02-01
US10370426B2 (en) 2019-08-06
TWI800478B (zh) 2023-05-01
JP6712322B2 (ja) 2020-06-17
JP2019504055A (ja) 2019-02-14
SA518391891B1 (ar) 2021-07-12
RS63541B1 (sr) 2022-09-30
ES2925098T3 (es) 2022-10-13
IL260318B2 (en) 2024-02-01
JP2019504057A (ja) 2019-02-14
KR20190062344A (ko) 2019-06-05
AU2016382393B2 (en) 2019-07-04
KR20190105542A (ko) 2019-09-17
IL260318A (en) 2018-08-30
TWI807580B (zh) 2023-07-01
US20180311315A1 (en) 2018-11-01
US20190153060A1 (en) 2019-05-23
CN116059389A (zh) 2023-05-05
US20210188937A1 (en) 2021-06-24
JP7030894B2 (ja) 2022-03-07
KR102285378B1 (ko) 2021-08-04
CR20180381A (es) 2019-01-14
ZA201804998B (en) 2019-05-29
HK1258177A1 (zh) 2019-11-08
TN2018000231A1 (en) 2019-10-04
CA3010182A1 (en) 2017-07-06
AU2019203891A1 (en) 2019-06-20
JP2022130723A (ja) 2022-09-06
HK1255834A1 (zh) 2019-08-30
AU2016382393A1 (en) 2018-08-02
US20220213164A1 (en) 2022-07-07
KR20200096184A (ko) 2020-08-11
IL260310A (en) 2018-08-30
WO2017116204A1 (ko) 2017-07-06
CL2022000557A1 (es) 2022-09-23
TW201730207A (zh) 2017-09-01
US11332508B2 (en) 2022-05-17
CN109071624B (zh) 2023-01-17
CN108699125B (zh) 2022-10-28
EP3398962A1 (en) 2018-11-07

Similar Documents

Publication Publication Date Title
CL2022000558A1 (es) Conjugado persistente de triple activador que activa el receptor de glucagón, glp-1 u gip (divisional 2 solicitud 202002033)
CL2023001910A1 (es) Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo
EA201791117A1 (ru) Частичные агонисты инсулинового рецептора
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza.
EA201790896A1 (ru) Пролекарства фенольных агонистов trpv1
UY37590A (es) COMPUESTOS MODULADORES DEL RECEPTOR DE HIDROCARBUROS ARÍLICOS (AhR)
CY1123892T1 (el) Κρυσταλλικες μορφες του 6-((6,7-διμεθοξυκιναζολιν-4-υλο)οξυ)-ν,2-διμεθυλοβενζοφουρανο-3-καρβοξαμιδιου
MX2020003217A (es) Coagonistas de accion prolongada de los receptores de glucagon y glp-1.
CL2018003045A1 (es) Semaglutida en afecciones cardiovasculares.
WO2017074798A3 (en) Long-acting co-agonists of the glucagon and glp-1 receptors
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
MY199261A (en) Long-acting conjugate of triple glucagon/glp-1/gip receptor agonist
EA201791456A1 (ru) Пептиды-антагонисты cgrp
EA201991576A1 (ru) Частичные агонисты инсулинового рецептора